EDAP Records First Three U.S. Orders for Ablatherm HIFU
November 12 2015 - 7:30AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, today announced that it signed contracts for the sale
of three Ablatherm® HIFU devices to prominent U.S. urology groups.
The Company expects to start shipping systems from its
manufacturing facility in France to U.S. locations within the next
ten days.
Marc Oczachowski, Chief Executive Officer of EDAP commented: "We
are extremely pleased to announce that we have in-hand our first
orders in the U.S., with three sales contracts signed and being
executed. Since FDA clearance of our Ablatherm Robotic HIFU device,
we have been receiving a significant number of queries from
urologists and other stakeholders in the urology community. Thanks
to our established sales and services network in the U.S., we are
diligently responding to this strong demand."
Oczachowski concluded: "We are very excited to see that our
commercialization plans are showing immediate results and that our
technology is generating such positive feedback from the U.S.
market."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Sep 2024 to Oct 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Oct 2023 to Oct 2024